Do’s and Dont’s while facing the increased war for talent.
A lot is happening in the world of Pharmaceuticals these days. Just as big pharma witnessed a lot of consolidation in the mid-late 2000s, the last few years have been the age of small- to mid-sized biotech/ pharmaceutical companies as they scale up for rapid growth. This is leading to some interesting challenges for them on the business and people front. The three realities facing the pharmaceutical industry today are:
The sector is scaling rapidly and there are hyper-inflated talent markets where demand exceeds supply
The small and mid-sized pharmaceutical industry is in the midst of some fascinating growth and change. Those with a strong pipeline, situated in the hot talent markets of Cambridge, MA, Dublin, Ireland, or New Jersey amongst others are seeing some exciting growth opportunities and similar talent challenges. While some might be on the verge of a rich pipeline, others are witnessing a move to commercialization all of which calls for scaling of talent processes at a speed that has not been seen before.
Employees want career progression and are not shy about moving companies for better pay and titles
The employee who is comfortably located in these markets with the right skills and experience is suddenly seeing the market open up with opportunities that present greater career choices along with significant powers to negotiate their way in. What they want is rapid career progression with the right pay that maintains their brand worth both from an internal and external equity standpoint. More importantly, no one is feeling shy in making demands on the titles they would like to see on their business cards.
Employers often succumb to pressures of attraction and retention in ways that might be causing bigger issues to organization design and employee morale
What the reality of the market and the employee needs means for the employer is a daily challenge on the attraction and retention front. Several companies find themselves with organizational bulges at the VP and director levels as skilled talent refuses to settle for anything less joining their company. This sets off a wave of internal angst and inequity as current employees feel disenfranchised if they feel the person being brought in negotiated their way to a higher title.
As organizations deal with these challenges, there are several steps or missteps that can propel them to a business advantage or disadvantage very quickly. Below are a few Do's and Don'ts as you look at this problem and try to solve it for your organization.
This is a dynamic sector which will only see more talent opportunities and challenges in the years to come. Setting the HR processes and approaches right from the beginning will be the key to success, not just for the organization itself but the industry as a whole.
Tonushree Mondal is talent, culture, and leadership consultant for her company Tonushree Mondal.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.